Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setanaxib + Pembrolizumab in Recurrent or Metastatic SCCHN
2023-509917-35-00Phase 2Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Setanaxib + Pembrolizumab with Placebo + Pembrolizumab (2 arms). Primary endpoint: Best percentage change in tumour size. Started May 2024; status: completed.
02
Drugs
setanaxib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-509917-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509917-35-00.